News
The FDA is reevaluating GlaxoSmithKline’s blood cancer drug Blenrep following mixed results from two phase 3 trials and mounting concerns about eye-related side effects and dosing. The agency is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback